NCT05712772

Brief Summary

The goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. The main questions this study aims to answer are:

  • Does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals?
  • Are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than young adults? Participants will complete:
  • A magnetic resonance imaging brain scan, in which we will examine the effect of blue versus red light on emotional brain function at rest and in response to rewards and losses.
  • A pupillometry test of sensitivity to blue vs red light
  • Clinical interviews and surveys
  • Screening measures for drug and alcohol use, MRI safety, and current pregnancy \[if relevant\]
  • Home sleep tracking with sleep diary and actigraphy for one week

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
3mo left

Started Jun 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jun 2023Jul 2026

First Submitted

Initial submission to the registry

January 25, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 3, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

June 14, 2023

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Last Updated

August 11, 2025

Status Verified

August 1, 2025

Enrollment Period

3.1 years

First QC Date

January 25, 2023

Last Update Submit

August 5, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Amygdala cerebral blood flow during Blue vs Red light exposure

    Cerebral blood flow will be assessed using pseudo-continuous arterial spin labeling collected during blue and red light exposures. Regional cerebral blood flow in the amygdala region of interest will be examined.

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Ventral Striatum cerebral blood flow during Blue vs Red light exposure

    Cerebral blood flow will be assessed using pseudo-continuous arterial spin labeling collected during blue and red light exposures. Regional cerebral blood flow in the ventral striatum region of interest will be examined.

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Amygdala activity (loss>neutral) during Blue vs Red light exposure

    This outcome will be measured during the an auditory probabilistic reward task, which is a computerized fMRI behavioral task. Activation is defined by blood oxygen dependent signal within an amygdala region of interest on loss versus neutral (no win/no loss) trials.

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Ventral Striatum activity (punish>neutral) during Blue vs Red light exposure

    This outcome will be measured during the an auditory probabilistic reward task, which is a computerized fMRI behavioral task. Activation is defined by blood oxygen dependent signal within a ventral striatum region of interest on win versus neutral (no win/no loss) trials.

    Collected during the blue and red light exposures during the MRI scan at the lab visit

Secondary Outcomes (9)

  • Medial prefrontal cortex cerebral blood flow during Blue vs Red light exposure

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Insula cerebral blood flow during Blue vs Red light exposure

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Ventromedial prefrontal cortex cerebral blood flow during Blue vs Red light exposure

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Amygdala-whole brain functional connectivity (loss>neutral) during Blue vs Red light exposure

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • Ventromedial prefrontal cortex activity (loss>neutral) during Blue vs Red light exposure

    Collected during the blue and red light exposures during the MRI scan at the lab visit

  • +4 more secondary outcomes

Study Arms (2)

Blue then Red Light

EXPERIMENTAL

Blue light (480 nm) then Red light (640 nm)

Other: Blue LightOther: Red Light

Red Light then Blue Light

EXPERIMENTAL

Red light (640 nm) then Blue light (480 nm)

Other: Blue LightOther: Red Light

Interventions

Blue light exposure

Blue then Red LightRed Light then Blue Light

Red light exposure

Blue then Red LightRed Light then Blue Light

Eligibility Criteria

Age12 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Elevated Depressive Symptoms \[PHQ9≥5 And (Item 1≥1 or Item 2≥1)\]
  • (If \<18yr) Parent or guardian can attend the baseline clinical interview

You may not qualify if:

  • Unable to read and write in English
  • Intellectual disability.
  • Left or mixed handedness
  • Changes to psychotropic medication type or dosage in the past 2 months
  • Lifetime bipolar disorder or schizophrenia, or substance/alcohol disorder in the past 3 months.
  • Factors influencing light and color sensitivity (i.e., color-blindness, serious ophthalmological conditions, photo-sensitizing medication).
  • Factors influencing the ability to maintain a stable sleep schedule (i.e., shift work, severe sleep disorders, extremely late or early sleep schedule).
  • Severe medical illness, neurological disorders, or history of head trauma.
  • Current pregnancy or nursing
  • MRI contraindication (e.g., metals in the body, recent tattoo, claustrophobia)
  • Positive alcohol or substance use screen at MRI visit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Western Psychiatric Hospital

Pittsburgh, Pennsylvania, 15213, United States

RECRUITING

MeSH Terms

Interventions

Blue LightRed Light

Intervention Hierarchy (Ancestors)

LightElectromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaOptical PhenomenaRadiationRadiation, Nonionizing

Study Officials

  • Adriane M Soehner, PhD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Adriane M Soehner, PhD

CONTACT

Allison Caswell, BS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: All participants will receive blue and red light exposures; order of red vs. blue light will be counterbalanced across participants.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 25, 2023

First Posted

February 3, 2023

Study Start

June 14, 2023

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

July 31, 2026

Last Updated

August 11, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will share

The investigators will complete and submit a National Data Archive (NDA) Data Sharing Agreement within 6 months of the Notice of Award Issue date. Study staff will upload data dictionary to the NDA website, and will review the NDA data definition for the measures collected and define the project's data definition harmonized to that standard. For measures not yet defined, project staff will work with the NDA staff to define the measure following NDA best practices. Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Study staff will use participants' personally identifiable information to generate NDA Global Unique Identifier (GUID) numbers for study participants. All data will be identified by GUID numbers only prior to submission to the NDA database. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA.

Time Frame
Raw data and data from descriptive/raw measures will be submitted on a semi-annual basis by July 15 and January 15 or the next business day. We also agree to submit to NDA the analyzed data yielded in our project (i.e., 12 months after accomplishment of each primary aim or objective, or immediately upon publication of the project's primary results, whichever occurs first). The PIs reserve the right to publish on the stated aims in a timely manner during the period of the award. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the award has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.
Access Criteria
Outside investigators must submit a 1) proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2) resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4) obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of human subjects protection training.
More information

Locations